JD Vance is a marijuana prohibitionist

Ohio Republican Senator JD Vance is running his Vice-Presidential campaign on an anti-marijuana platform that promotes old and worn-out fallacies about cannabis that were debunked before he was born.

Vance says marijuana causes violence and that it bears a direct relationship to violent crime, despite numerous refutations from historical and scientific studies. His attitude toward marijuana is depicted in a movie made of his life and directed by Ron Howard, Hillbilly Elegy, that portrays his mother’s heroin addiction. The picture’s focus is on her drug use rather than any information that might be useful in determining her overall mental condition. A mental disorder could explain her non-drug-related misbehavior in addition to her drug problem. Based on her movie depiction, one possible diagnosis might be bipolar disorder.

The movie script also reinforces a common marijuana myth. It has young JD refusing to try marijuana while telling his teenage stepbrother that marijuana is a gateway drug. If a gateway exists, it is drug illegality, not another drug. Legal alcohol or legal aspirin alone typically do not lead to heroin use. Illegal connections are needed to buy heroin.

Being anti-marijuana doesn’t benefit Senator Vance now that his home state of Ohio has legal recreational weed. His emphasis on prohibition alienates voters when he says that immigrants smuggle fentanyl into the U.S. where it’s used as a genocidal weapon aimed at MAGAs, and that Joe Biden ordered it to happen with his open border policies.

Senator Vance ignores the fact that fentanyl and methamphetamine trafficking arrests consist primarily of red state American citizens who own the expensive equipment and connections needed to move contraband. Given the lure of easy drug money, and with immigrants conveniently shouldering the blame for smuggled drugs, immigration is not their immediate concern. However, by linking legal or illegal immigrants to fentanyl ODs in the U.S., Vance promotes Donald Trump’s anti-immigrant policies and the building of Trump’s ill-fated border wall.

Political novices and science illiterate demagogues like JD Vance are encouraged by moral mythologies that reinforce tribal fears of the other, and with it a fanatical desire to magically simplify political and social issues by prohibiting marijuana or supporting and voting tyrants into public office. Vance doesn’t get the idea that tyranny never lasts, that old tyrants die off, that the Big Lie has a time limit, and that it’s difficult in a democracy to predict how long a big lie will be believed. The shelf life of marijuana fallacies expired decades ago. Recent Pew Research polls indicate 88-percent of Americans believe marijuana should be legal for medical or recreational use.

This entry was posted in Servetus. Bookmark the permalink.

6 Responses to JD Vance is a marijuana prohibitionist

  1. Vance sounds a lot like that violent thug Jeff Landry. Landry used to be a narcotics officer and sheriff’s deputy, which should tell you that he is unfit for office.

  2. Servetus says:

    CBD alleviated symptoms of Leigh syndrome in a study done at the University of Barcelona:

    6-Sep-2024 — …daily administration of cannabidiol (CBD), a substance obtained from the cannabis plant, extends lifespan and improves symptoms associated with Leigh syndrome. This severe mitochondrial disease affecting children is characterised by a progressive decline in cognitive and motor functions and premature death. The research group also demonstrated in both mice and fibroblasts from children with the disease that CBD improves cellular function.

    Leigh syndrome is a rare mitochondrial disease particularly affecting the organs and tissues that require most energy: the muscles and nervous system. It is characterized by progressive neuromuscular decline and premature death, and there are currently no approved treatments. That is why it is urgent to find a solution for patients suffering from this disease. […]

    …daily administration of CBD is a promising treatment option. Through its multiple action it provides antioxidant, anti-inflammatory and anticonvulsant effects, which improve the symptomatology and help recover cell functions in patients. The study was conducted with two different Leigh syndrome mouse models, as well as with fibroblast cells from patients.

    The results revealed that CBD acts at many levels within the cell, including activating a protein inside the cell nucleus known as PPARγ. This protein regulates the expression of many genes involved in the immune response, oxidation and mitochondrial function, and has been seen to be altered by the disease. Moreover, CBD increases the expression of the metallothionein protein, which enhances its antioxidant response.

    In the animal models, cannabidiol administration improved neuropathology in the affected brain regions, breathing abnormalities and social deficits, and also delayed motor decline and neurodegenerative signs. In addition, mice receiving treatment lived significantly longer than those with no treatment. In the fibroblast cells from patients, CBD improved their antioxidant processes.

    “The benefits we observed, together with CBD’s safe and well-tolerated profile, show it to be a truly promising treatment for patients with Leigh syndrome”, explains Dr. Albert Quintana, researcher at the INc-UAB and lecturer in the Department of Cellular Biology, Physiology and Immunology at the UAB.

    AAAS Public Science News Release: Cannabidiol demonstrated to alleviate symptoms of Leigh syndrome

    Nature Communications: Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models

    Authors: Emma Puighermanal, Marta Luna-Sánchez, Alejandro Gella, Gunter van der Walt, Andrea Urpi, María Royo, Paula Tena-Morraja, Isabella Appiah, Maria Helena de Donato, Fabien Menardy, Patrizia Bianchi, Anna Esteve-Codina, Laura Rodríguez-Pascau, Cristina Vergara, Mercè Gómez-Pallarès, Giovanni Marsicano, Luigi Bellocchio, Marc Martinell, Elisenda Sanz, Sandra Jurado, Francesc Xavier Soriano, Pilar Pizcueta & Albert Quintana.

  3. Servetus says:

    21.9-percent of fatal drug ODs in 2022 were among people with a diagnosable mental health disorder:

    August 29, 2024 — ABSTRACT: Drug overdose deaths remain a public health crisis in the United States; nearly 107,000 and nearly 108,000 deaths occurred in 2021 and 2022, respectively. Persons with mental health conditions are at increased risk for overdose. In addition, substance use disorders and non–substance-related mental health disorders (MHDs) frequently co-occur. Using data from CDC’s State Unintentional Drug Overdose Reporting System, this report describes characteristics of persons in 43 states and the District of Columbia who died of unintentional or undetermined intent drug overdose and had any MHD. In 2022, 21.9% of persons who died of drug overdose had a reported MHD. Using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria, the most frequently reported MHDs were depressive (12.9%), anxiety (9.4%), and bipolar (5.9%) disorders. Overall, approximately 80% of overdose deaths involved opioids, primarily illegally manufactured fentanyls. Higher proportions of deaths among decedents with an MHD involved antidepressants (9.7%) and benzodiazepines (15.3%) compared with those without an MHD (3.3% and 8.5%, respectively). Nearly one quarter of decedents with an MHD had at least one recent potential opportunity for intervention (e.g., approximately one in 10 decedents were undergoing substance use disorder treatment, and one in 10 visited an emergency department or urgent care facility within 1 month of death). Expanding efforts to identify and address co-occurring mental health and substance use disorders (e.g., integrated screening and treatment) and strengthen treatment retention and harm reduction services could save lives. […]

    Morbidity and Mortality Report: Reported Non–Substance-Related Mental Health Disorders Among Persons Who Died of Drug Overdose — United States, 2022

    Authors: Amanda T. Dinwiddie, MPH; Stephanie Gupta, MPH; Christine L. Mattson, PhD; Julie O’Donnell, PhD; Puja Seth, PhD.

  4. Servetus says:

    Neural pathways are elucidated that explain morphine’s strong analgesic effect:

    30-AUG-2024 — Opioids have been used for medicinal and recreational purposes for millennia. They constitute a broad group of pain-relieving medicines, which includes morphine, that remain effective treatments for managing pain today. Opioids attach to opioid receptors in brain cells, not only blocking pain messages but also boosting feelings of pleasure. As a result, the use of opioids for pain relief has led to growing dependence, abuse, overdose, and death. Insight into the cells and neural pathways that provide pain relief is needed to explain how morphine can have such a powerful analgesic effect as well as how they differ from neurons and pathways eliciting feelings of euphoria, well-being, and addiction. […]

    We found that the RVM consists of multiple molecular types of γ-aminobutyric acid–mediated (GABAergic) neurons as well as a few types of glutamatergic and serotonergic neurons. Among these, morphine activated a select set of neurons, which together formed a “morphine ensemble.” Synthetic activation of the genetically captured morphine ensemble produced mechanical pain relief, mimicking the effects of morphine, and its inactivation completely abolished the effects of morphine on pain. […]

    We discovered that neural activity alone in the RVM induces the key features of morphine-induced mechanical pain relief, and when this activity is inhibited, morphine has little effect. Pain relief is mediated by glutamatergic RVMBDNF neurons projecting to inhibitory SCGal neurons, which attenuate incoming pain signaling in the spinal cord on the way to the brain. Within this circuit, BDNF is an essential component modulating neurotransmission. Finding the molecular identity of neurons that regulate morphine-induced mechanical antinociception advances the search for alternative therapeutic strategies to provide pain relief across various pain conditions. […]

    Science: Morphine-responsive neurons that regulate mechanical antinociception

    Authors: Michael P. Fatt, Ming-Dong Zhang, Jussi Kupari, Müge Altınkök, Yunting Yang, Yizhou Hu, Per Svenningsson, and Patrik Ernfors.

  5. Servetus says:

    Researchers from the Nanjing Agricultural University Academy of Science have discovered a gene in marijuana that regulates the quantity of flowering sites on the plant:

    10-Sep-2024 — Scientists have identified a crucial gene, CsMIKC1, that controls the number of flowering sites in Cannabis sativa, a finding that could significantly enhance both medicinal and grain yields. The study reveals how CsMIKC1 drives inflorescence development, offering new pathways to boost productivity in Cannabis cultivation. Through gene editing and functional analysis, the researchers demonstrated the gene’s impact on flower production, highlighting its potential to transform agricultural practices. This breakthrough sets the stage for developing high-yielding Cannabis strains tailored for both medical and industrial use. […]

    The study identifies CsMIKC1, a MIKC-type MADS-box transcription factor, as a pivotal regulator of inflorescence development in Cannabis sativa. Using CRISPR-Cas9 gene editing, the team examined how CsMIKC1 mutations and over-expression influence flower and grain production. Their findings offer fresh insights into the genetic architecture of inflorescence, underscoring the gene’s significant role in enhancing crop yields and presenting new avenues for genetic improvement. […]

    The researchers also found that CsMIKC1 is influenced by ethylene signaling pathways, as seen in the reduced ethylene sensitivity of CsBPC2 mutants. Applying external ethylene stimulated CsMIKC1 expression, enhancing flower production and suggesting practical applications in commercial Cannabis farming. By identifying key genes regulated by CsMIKC1, the study maps a comprehensive genetic network governing inflorescence formation, offering critical insights for future crop enhancement strategies. […]

    AAAS Public Science News Release: Boosting cannabis production: The science behind bud abundance

    Horticulture Research: CsMIKC1 regulates inflorescence development and grain production in Cannabis sativa plants

    Authors: Gencheng Xu, Yongbei Liu, Shuhao Yu, Dejing Kong, Kailei Tang, Zhigang Dai, Jian Sun, Chaohua Cheng, Canhui Deng, Zemao Yang, Qing Tang, Chao Li, Jianguang Su, Xiaoyu Zhang.

  6. Servetus says:

    Millions of people with clinical depression could benefit from psilocybin therapy if approved by the FDA:

    13-Sep-2024 — Atlanta, Georgia – In the wake of mounting evidence for the efficacy of psychedelic-assisted therapies, the U.S. Food and Drug Administration (FDA) is considering approving psilocybin, the active ingredient in “magic mushrooms,” for treating depression in the near future. As this watershed moment approaches, a critical question arises: Just how many people might stand to benefit from this promising but still unproven therapy? […]

    By analyzing national survey data on depression prevalence and treatment in conjunction with the eligibility criteria from recent landmark clinical trials, the researchers determined that between 56% and 62% of patients currently receiving treatment for depression—amounting to a staggering 5.1 to 5.6 million individuals—could qualify for psilocybin therapy if approved. […]

    The researchers caution that these projections are highly contingent on the precise FDA approval parameters and subsequent real-world implementation factors. Insurance coverage decisions, availability of trained practitioners, and regional variations in access could all considerably constrain the ultimate uptake of psilocybin therapy. Additionally, if approval encompasses off-label use for conditions beyond depression, demand could further surge in unpredictable ways.

    “While our analysis is a crucial first step, we’ve only scratched the surface in understanding the true public health impact psilocybin therapy may have,” said Dr. Charles Raison, a collaborator on the study and the lead investigator on one of the largest clinical trials looking at the efficacy of psilocybin therapy for depression. […]

    AAAS Public Science News Release: Millions of depressed Americans could benefit from psychedelic therapy, study finds–new analysis reveals over half of patients treated for depression may be eligible for psilocybin-assisted therapy if FDA-approved

Leave a Reply

Your email address will not be published. Required fields are marked *